Inactive lipids that accompany the endocannabinoid 2-AG in the body amplify its signal at cannabinoid receptors. The 'entourage effect' was originally about endogenous biochemistry, not cannabis terpenes.
Anyone who has heard the term 'entourage effect' and wants to know what it originally meant versus how the industry uses it.
Inactive alone, amplifying together — the original entourage effect
The Backstory
The word that launched a billion dollars of marketing started as a quiet observation about fat molecules in a Jerusalem laboratory.
In 1998, Shimon Ben-Shabat — a PhD student working in Raphael Mechoulam's lab at the Hebrew University — noticed something strange about 2-AG, the endocannabinoid his group had helped identify three years earlier. In the body, 2-AG was never alone. It was always accompanied by two other lipid molecules — 2-linoleoyl-glycerol and 2-palmitoyl-glycerol. Structurally similar, but pharmacologically silent. They didn't bind cannabinoid receptors. They didn't activate anything. By every standard measure, they were inactive.
But when Ben-Shabat tested 2-AG with its companions present, the active molecule worked better. Stronger binding. Greater enzyme inhibition. Enhanced behavioral effects in mice. The inactive compounds were amplifying the active one.
He and Mechoulam gave this phenomenon a name: the entourage effect.
It was a precise, technical observation about endogenous lipid biochemistry. It would become the most marketable concept in cannabis history.
What They Actually Found
How They Did It
The Original Entourage Effect Experiment
Identify 2-AG companions
When 2-AG was extracted from tissues, two other fatty acid glycerol esters consistently appeared alongside it: 2-linoleoyl-glycerol (2-Lino-Gl) and 2-palmitoyl-glycerol (2-Palm-Gl).
These are structurally similar to 2-AG but use different fatty acid chains (linoleic and palmitic acid instead of arachidonic acid)
Test companions alone
Neither 2-Lino-Gl nor 2-Palm-Gl bound to cannabinoid receptors. Neither inhibited adenylyl cyclase. Neither produced cannabinoid behaviors in mice. By themselves, they were pharmacologically inert.
This is critical — these molecules do absolutely nothing on their own
Test 2-AG alone vs. 2-AG with companions
When 2-AG was tested in the presence of its companion esters, its apparent binding to cannabinoid receptors increased significantly. Its capacity to inhibit adenylyl cyclase was potentiated.
The inactive compounds were making the active one more effective
In vivo confirmation
In mice, 2-AG with its companion esters produced greater motor inhibition, stronger analgesia, and more pronounced hypothermia than 2-AG alone — the cannabinoid tetrad effects were amplified.
The effect wasn't just a test-tube artifact — it held up in living animals
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31
The finding was elegant and unexpected. The body wasn't just making 2-AG — it was making 2-AG packaged with helper molecules that boosted its signal. The endocannabinoid system had built-in amplifiers.
Inactive alone, amplifying together
2-linoleoyl-glycerol and 2-palmitoyl-glycerol do not bind CB1 or CB2 receptors and produce no cannabinoid effects on their own. But in the presence of 2-AG, they significantly potentiate its receptor binding, enzyme inhibition, and in vivo behavioral effects. The mechanism was proposed as a 'novel route for molecular regulation of endogenous cannabinoid activity.'
This is different from simple synergy (two active compounds working together). This is inactive compounds enhancing an active one — a subtler, more surprising form of biological cooperation.
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31
The Team
The paper had ten authors spanning two continents. At its center was Mechoulam's lab in Jerusalem — the same lab that had isolated THC in 1964, discovered anandamide in 1992, and co-identified 2-AG in 1995.
Shimon Ben-Shabat was the first author — Mechoulam's PhD student who would go on to become a professor at Ben-Gurion University of the Negev. His doctoral work focused on the biochemistry of endocannabinoids, and this paper emerged from his close study of what accompanied 2-AG in biological extracts.
Raphael Mechoulam was the senior author, now in his late sixties, still producing landmark findings. The entourage effect concept was characteristic of his approach: instead of focusing on a single molecule in isolation, he asked what the molecule's biological context looked like.
The author list also included Ester Fride (behavioral pharmacology), Zvi Vogel (receptor biology), and a Naples contingent — Tiziana Bisogno, Luciano De Petrocellis, and Vincenzo Di Marzo — who were among the world's leading endocannabinoid biochemists. The Italian collaboration brought expertise in lipid metabolism and endocannabinoid synthesis pathways.
The funding came from NIDA (grant DA 9789) — the same NIH institute that had funded much of Mechoulam's career in endocannabinoid discovery.
What "Entourage" Actually Meant
The paper's title was precise: "An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity."
Every word matters:
- Inactive — the companion molecules do nothing on their own
- Endogenous — the body makes them, alongside 2-AG
- Fatty acid glycerol esters — structurally specific lipids, not random compounds
- Enhance — they amplify, not replace, the active molecule's effects
The "entourage" was a metaphor: 2-AG travels with a retinue. The supporting cast doesn't perform but makes the star's performance better.
Myth vs. Reality
The entourage effect was originally about cannabis terpenes and cannabinoids working together.
The original 1998 entourage effect had nothing to do with cannabis plants, terpenes, or cannabinoids working together. It described how inactive endogenous lipids in the body enhance the activity of the endocannabinoid 2-AG. The concept was later extended to cannabis phytochemistry by Russo in 2011, who proposed that plant terpenes might similarly enhance plant cannabinoids. This extension — from endogenous lipids to plant compounds — is a hypothesis, not a finding. The original entourage effect is about the body's own biochemistry.
The Evidence
Ben-Shabat et al. (1998) studied 2-AG and its endogenous fatty acid glycerol ester companions. No plant-derived compounds were involved. Russo (2011) explicitly extended the concept to phytocannabinoid-terpenoid interactions in his 'Taming THC' review.
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31; Russo (2011), Br J Pharmacol 163:1344-1364
Why Inactive Compounds Matter
The finding opened a window into how the endocannabinoid system actually regulates itself. If 2-AG's effects depend on what's around it, then measuring 2-AG levels alone doesn't tell you how strong the signal actually is. The system has a built-in volume control that depends on the presence of non-signaling lipids.
Biological Mechanism
How the Entourage Amplifies 2-AG
2-AG is synthesized
When a postsynaptic neuron needs to send a retrograde signal, it produces 2-AG from membrane lipids via DAGLα. This is the active endocannabinoid.
Companion esters are co-produced
The same membrane lipid pool that generates 2-AG also produces 2-linoleoyl-glycerol and 2-palmitoyl-glycerol. They emerge together from the same biochemical source.
Companions do NOT bind receptors
2-Lino-Gl and 2-Palm-Gl have no affinity for CB1 or CB2 receptors. They cannot activate cannabinoid signaling on their own.
But they potentiate 2-AG
Through mechanisms not fully characterized, the companion esters increase 2-AG's apparent binding affinity and functional efficacy. Possible mechanisms include: competing for degradation enzymes (protecting 2-AG from breakdown), altering membrane dynamics, or indirect receptor modulation.
Net effect: stronger signal from same amount of 2-AG
In vivo, the combination produces greater analgesia, more motor inhibition, and stronger hypothermia than 2-AG alone. The endocannabinoid signal is amplified without producing more endocannabinoid.
Ben-Shabat et al. (1998), Eur J Pharmacol 353:23-31
This has implications for pharmaceutical development. If you want to boost endocannabinoid signaling, you don't necessarily need more 2-AG — you might just need to preserve its entourage. FAAH and MAGL inhibitors (which prevent endocannabinoid degradation) are one approach. But another, suggested by this paper, is to ensure the companion esters remain intact alongside 2-AG.
From Endogenous Biology to Cannabis Marketing
The conceptual leap from Ben-Shabat's endogenous lipid observation to cannabis industry marketing happened in stages:
Research Timeline
How 'Entourage Effect' Changed Meaning
Ben-Shabat & Mechoulam publish the original finding
Inactive endogenous esters enhance 2-AG activity in the body. The term 'entourage effect' is coined for endogenous biochemistry.
Russo & Guy propose THC-CBD synergy
The combination concept extends from endogenous lipids to plant cannabinoids — CBD modifies THC's effects.
Russo extends concept to terpenes
'Taming THC' proposes that plant terpenes enhance cannabinoid effects — the entourage effect becomes about the whole cannabis plant.
Cannabis industry adopts the term
Dispensaries market by terpene profile. 'Entourage effect' becomes shorthand for 'whole plant is better.' The original endogenous meaning is largely forgotten.
Finlay et al. challenge the mechanism
Terpenes don't activate CB1/CB2 — if the plant entourage effect exists, it works differently than the endogenous one.
Multiple sources
The irony is that the original entourage effect — endogenous lipids potentiating endogenous cannabinoids — is well-supported experimental science. The extended version — plant terpenes potentiating plant cannabinoids — is a hypothesis that hasn't been consistently confirmed. The marketing appropriated the credibility of the original to sell the unproven extension.
What We Still Don't Know
Twenty-five years after publication, several questions remain:
Mechanism: How exactly do 2-Lino-Gl and 2-Palm-Gl potentiate 2-AG? Proposed mechanisms include enzyme competition (protecting 2-AG from MAGL degradation), membrane effects (changing local lipid environment around receptors), and allosteric modulation. None has been definitively confirmed.
Generalizability: Does the entourage principle apply to anandamide and its companion lipids? To other lipid signaling systems beyond endocannabinoids? The paper proposed it as a "novel route for molecular regulation" — suggesting it might be a general biological principle.
Clinical relevance: Could measuring entourage ester levels alongside 2-AG provide better biomarkers for endocannabinoid deficiency? If 2-AG levels look normal but companion ester levels are depleted, the effective signal could still be deficient.
Related Research
The Endocannabinoid Entourage
This paper coined the concept that inactive molecules can enhance active endocannabinoid signaling. These are the studies that built the system it describes and the concept it spawned.
A second endocannabinoid that modulates long-term potentiation
Stella, Schweitzer & Piomelli (1997)
2-AG in the brain — the active molecule whose signal the entourage amplifies
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
Devane, Hanuš, Mechoulam et al. (1992)
Anandamide — the first endocannabinoid, from the same lab that would discover the entourage concept six years later
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Russo (2011)
The review that extended the entourage concept from endogenous lipids to plant terpene-cannabinoid interactions
Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors
Finlay et al. (2020)
The study that tested whether plant terpenes produce an entourage effect at CB1/CB2 — and found they don't
The molecular logic of endocannabinoid signalling
Piomelli (2003)
The comprehensive review of endocannabinoid biochemistry — the system whose regulation the entourage modifies
What is the original entourage effect?
The original entourage effect, described by Ben-Shabat and Mechoulam in 1998, is a specific biochemical finding: inactive fatty acid glycerol esters that accompany the endocannabinoid 2-AG in the body significantly enhance its ability to bind cannabinoid receptors and produce biological effects. The "entourage" refers to companion molecules that do nothing on their own but amplify the active molecule's signal. This is about the body's own biochemistry — not about cannabis plants.
Is the entourage effect about terpenes?
Not originally. The 1998 paper studied endogenous lipids in the body, not cannabis plant compounds. The concept was extended to cannabis terpenes by Ethan Russo in 2011, who proposed that plant terpenes might similarly enhance plant cannabinoids. This extension is a hypothesis — partially supported by preclinical data but not consistently confirmed at the receptor level. The original endogenous entourage effect is well-supported. The plant terpene extension is debated.
Why does this paper matter if it's not about cannabis?
Because it established a fundamental principle of endocannabinoid regulation: the signal depends on context, not just on the signaling molecule. This has implications for understanding endocannabinoid tone, for developing better biomarkers for conditions like endocannabinoid deficiency, and for pharmaceutical development. It also gave a name — "entourage effect" — to a concept that would reshape the entire cannabis industry, even though the industry's use of the term has drifted far from the paper's original meaning.
What the researchers found
Inactive fatty acid glycerol esters (2-linoleoyl-glycerol and 2-palmitoyl-glycerol) that naturally accompany 2-AG in the body significantly potentiate its cannabinoid receptor binding, adenylyl cyclase inhibition, and in vivo behavioral effects (motor inhibition, analgesia, hypothermia). The inactive compounds amplify the active one's signal — the first demonstration of the 'entourage effect.'
Why it matters
Coined the term 'entourage effect' and established that endocannabinoid signaling depends on biological context, not just the signaling molecule itself. Proposed a new route for molecular regulation of cannabinoid activity. The concept was later extended to cannabis phytochemistry and became the most influential idea in the cannabis industry.
The numbers in context
Two companion esters identified: 2-linoleoyl-glycerol and 2-palmitoyl-glycerol. Neither binds CB1 or CB2 alone. Both significantly potentiate 2-AG binding, adenylyl cyclase inhibition, and in vivo effects (motor inhibition, analgesia, hypothermia in mice).
How the study worked
In vitro: radioligand binding assays and adenylyl cyclase inhibition assays at CB1 and CB2 receptors. In vivo: cannabinoid tetrad testing in mice (motor inhibition, ring immobility, hot plate analgesia, hypothermia). Compared 2-AG alone vs. 2-AG with companion esters.
Who was studied
In vitro receptor assays; in vivo mouse behavioral testing
What this study cannot tell us
The exact mechanism of potentiation was not determined. Whether the companion esters protect 2-AG from enzymatic degradation, alter membrane dynamics, or act through allosteric mechanisms remains unresolved 25+ years later. The extension from endogenous lipids to plant compounds (terpenes) was not part of this study.
How to read the evidence
Direct experimental evidence from both in vitro (receptor binding, enzyme inhibition) and in vivo (mouse behavioral testing) assays. Published in a respected pharmacology journal from Mechoulam's lab. The endogenous entourage effect is well-supported. The extension to plant compounds was not part of this study.
When this study was published
Published in 1998. The original endogenous entourage effect finding has not been contested. The mechanism of potentiation remains incompletely characterized. The term has been co-opted by the cannabis industry for a different (and less proven) claim about plant compound synergies.
The bigger picture
This paper established that biological signaling depends on context, not just the signal itself. The endocannabinoid system has built-in amplifiers. The concept became the most influential idea in the cannabis industry when extended to plant compounds — but the industry's version of the entourage effect has drifted far from the paper's original, precise meaning.
Questions still open
- What is the exact mechanism of potentiation? Does the entourage principle apply to anandamide and its companions? Could measuring entourage ester levels improve endocannabinoid deficiency biomarkers?
Common questions
Read the original research
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
Eur J Pharmacol
European Journal of Pharmacology — one of the leading pharmacology journals, publishing research on drug action and therapeutics since 1967.
Citation
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. https://doi.org/10.1016/s0014-2999(98)00392-6